16th Nov 2021 14:31
PureTech Health PLC - clinical-stage biotherapeutics company - Reports the results from a phase 1 trial evaluating multiple ascending doses and the food effect of LYT-100. Topline results from this study were previously announced in November 2020 and demonstrated that LYT-100 was well-tolerated in healthy volunteers under both fed and fasting conditions. "The data set from the completed Phase 1 MAD study, including a favorable safety and tolerability profile, reaffirms our belief that LYT-100 has the potential to be an attractive therapeutic option across a range of conditions," says Head of Innovation Michael Chen.
LYT-100 is PureTech's wholly-owned therapeutic candidate that is being advanced for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow.
Current stock price: 338.55 pence, up 1.5%
Year-to-date change: down 15%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
PureTech